Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 160

Similar articles for PubMed (Select 22941848)

1.

Extended-release/long-acting opioid REMS may fill the need for prescribers' appropriate use education.

Nicholson SC, Evanyo K, Salinas GD, Roepke N, Burton BS, Susalka D.

J Opioid Manag. 2012 Jul-Aug;8(4):212-6. doi: 10.5055/jom.2012.0118.

PMID:
22941848
2.

Class-wide REMS for extended-release and long-acting opioids: potential impact on pharmacies.

Matthews ML.

J Am Pharm Assoc (2003). 2013 Jan-Feb;53(1):e1-7. doi: 10.1331/JAPhA.2013.12025. Review.

PMID:
23636166
3.

Evolution of opioid risk management and review of the classwide REMS for extended-release/long-acting opioids.

Stanos S.

Phys Sportsmed. 2012 Nov;40(4):12-20. doi: 10.3810/psm.2012.11.1975. Review.

PMID:
23306411
4.
5.

Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics: considerations for palliative care practice.

Gudin J.

J Pain Palliat Care Pharmacother. 2012 Jun;26(2):136-43. doi: 10.3109/15360288.2012.679724.

PMID:
22764852
6.

Opioid risk management: understanding FDA mandated risk evaluation and mitigation strategies (REMS).

Sloan PA.

J Opioid Manag. 2009 May-Jun;5(3):131-3. No abstract available.

PMID:
19662921
7.

Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies.

Slevin KA, Ashburn MA.

J Opioid Manag. 2011 Mar-Apr;7(2):109-15.

PMID:
21561034
8.

Blueprint for prescriber continuing education program.

Center For Drug Evaluation And Research Food And Drug Administration.

J Pain Palliat Care Pharmacother. 2012 Jun;26(2):127-30. doi: 10.3109/15360288.2012.680013.

PMID:
22764849
9.

The Food and Drug Administration risk evaluation and mitigation strategy.

Craig DS.

J Pain Palliat Care Pharmacother. 2010 Jun;24(2):145-8. doi: 10.3109/15360281003713834.

PMID:
20504137
10.

Manufacturers argue against mandatory training for opioid prescribers.

Traynor K.

Am J Health Syst Pharm. 2010 Jan 15;67(2):96. doi: 10.2146/news100007. No abstract available.

PMID:
20065261
11.

Shared risk evaluation mitigation strategy for all immediate-release transmucosal fentanyl dosage forms.

Food And Drug Administration, Public Health Service, U.S. Department Of Health And Human Services.

J Pain Palliat Care Pharmacother. 2012 Jun;26(2):123-6. doi: 10.3109/15360288.2012.677946.

PMID:
22764848
12.
13.

US Food and Drug Administration's Risk Evaluation and Mitigation Strategy for extended-release and long-acting opioids: pros and cons, and a European perspective.

Mercadante S, Craig D, Giarratano A.

Drugs. 2012 Dec 24;72(18):2327-32. doi: 10.2165/11642230-000000000-00000. Review.

PMID:
23116252
14.
15.

Are opioid risk evaluation and mitigation strategies (REMS) interrupting your sleep?

Craig DS.

J Pain Palliat Care Pharmacother. 2012 Jun;26(2):134-5. doi: 10.3109/15360288.2012.680011.

PMID:
22764851
16.

The Food and Drug Administration opioid Risk Evaluation and Mitigation Strategy.

Lipman AG.

J Pain Palliat Care Pharmacother. 2009;23(3):219-21. doi: 10.1080/15360280903098325. No abstract available.

PMID:
19670017
17.

Curbing the opioid epidemic in the United States: the risk evaluation and mitigation strategy (REMS).

Nelson LS, Perrone J.

JAMA. 2012 Aug 1;308(5):457-8. doi: 10.1001/jama.2012.8165. No abstract available.

PMID:
22851109
18.

REMS; red tape, or a remedy for opioid abuse?

Porada S.

J Fam Pract. 2011 Sep;60(9 Suppl):S55-62. No abstract available.

PMID:
22442761
19.

Considerations for the upcoming FDA REMS proposal.

Peppin JF, Coleman JJ, Kirsh KL.

J Opioid Manag. 2011 May-Jun;7(3):173-6. No abstract available.

PMID:
21823548
20.

Current status and evolving role of abuse-deterrent opioids in managing patients with chronic pain.

Webster L, St Marie B, McCarberg B, Passik SD, Panchal SJ, Voth E.

J Opioid Manag. 2011 May-Jun;7(3):235-45. Review.

PMID:
21823554
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk